Table 2.
Univariate analysis for PFS.
| N (%) | 3-year RFS (95% CI) | P | |
|---|---|---|---|
|
| |||
| Median PFS for entire cohort | 266 | 92.7 (88–95.6) | |
|
| |||
| Age | 0.008* | ||
|
| |||
| Stage | 0.029* | ||
| I | 182 (68.4) | 97.1 (92.4–98.9) | |
| II | 18 (6.8) | 93.3 (61.3–99) | |
| III/IV | 66 (24.8) | 83.8 (71.2–91.3) | |
|
| |||
| CA125 | 0.003 | ||
| ≤ 35 | 143 (53.8) | 96.7 (91.3–98.7) | |
| >35 | 50 (18.8) | 86.9 (71.3–94.3) | |
| NA | 73 (27.4) | ||
|
| |||
| Histology | 0.079 | ||
| Serous | 196 (73.7) | 90.8 (84.9–94.5) | |
| Other | 70 (26.3) | 100 | |
|
| |||
| Invasive implants | <0.001 | ||
| Yes | 36 (13.5) | 77.2 (56–89) | |
| No | 229 (86.1) | 95.8 (91.4–98) | |
| NA | 1 (0.4) | ||
|
| |||
| Ascites | 0.227 | ||
| Yes | 51 (19.2) | 92.9 (87.5–96) | |
| No | 215 (80.8) | 92.5 (78.4–97.5) | |
|
| |||
| Lymphadenectomy | 0.394 | ||
| Yes | 128 (48.1) | 92.8 (85.5–96.5) | |
| No | 138 (51.9) | 92.7 (85.2–96.5) | |
|
| |||
| Micropapillary features (serous histology) | <0.001 | ||
| Yes | 36 (18.4) | 75.9 (55.6–87.8) | |
| No | 160 (81.6) | 94.3 (88.4–97.3) | |
|
| |||
| Residual disease | <0.001 | ||
| Yes | 11 (4.1) | 70 (32.9–82.9) | |
| No | 250 (94) | 95 (90.6–97.4) | |
| Unknown | 5 (1.9) | ||
|
| |||
| Fertility-sparing surgery | 0.034 | ||
| Yes | 95 (35.7) | 98.7 (91.2–99.8) | |
| No | 171 (64.3) | 89.9 (83.3–94) | |
|
| |||
| Completion surgery after fertility-sparing surgery | 0.018 | ||
| Yes | 37 (38.9) | 100 | |
| No | 58 (61.1) | 97.7 (84.6–99.7) | |
*
P-values were obtained using Cox proportional hazards model; other p values obtained using Wilcoxon Gehan test